MedTrace Logo

Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer

NCT01826877 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-08-04

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of autologous dendritic cells in treating patients with metastatic kidney cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.

Conditions

Interventions

BIOLOGICAL

AdGMCAIX-transduced autologous dendritic cells

Given ID

BIOLOGICAL

therapeutic autologous dendritic cells

Given ID

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • Kite, A Gilead Company

    collaborator INDUSTRY

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Alexandra Drakaki, MD · Jonsson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-14
Primary Completion
2018-07-03
Completion
2021-05-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01826877 on ClinicalTrials.gov